ANTX
AN2 Therapeutics, Inc.
Biotechnology
Market Cap$130M
5Y Perf.-68.5%
Build Your Comparison
Side-by-side financial analysisANTX
ENTA
Try popular comparisons:
Stock Comparison
ANTX vs ENTA
Revenue, margins, valuation, and 5-year total return — side by side.
ENTA
Enanta Pharmaceuticals, Inc.
Biotechnology
Market Cap$276M
5Y Perf.-83.3%
ANTX vs ENTA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ANTX |  ENTA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $130M | $276M |
| Revenue (TTM) | $0.00 | $69M |
| Net Income (TTM) | $-35M | $-62M |
| Gross Margin | — | 98.3% |
| Operating Margin | — | -87.2% |
| Total Debt | $0.00 | $201M |
| Cash & Equiv. | $20M | $32M |
ANTX vs ENTA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ANTX
ENTA
| Stock | Mar 22 | Jun 26 | Return |
|---|---|---|---|
| AN2 Therapeutics, I… (ANTX) | 100 | 31.5 | -68.5% |
| Enanta Pharmaceutic… (ENTA) | 100 | 16.7 | -83.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANTX vs ENTA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ANTX leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Enanta Pharmaceuticals, Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ANTX emerged as the overall leader. Track its performance:
ANTX
AN2 Therapeutics, Inc.
The Income Pick
ANTX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.42
- EPS growth 32.6%
- -39.4% 10Y total return vs ENTA's -48.3%
Best for: income & stability and growth exposure
ENTA
Enanta Pharmaceuticals, Inc.
The Niche Pick
ENTA is the clearest fit if your priority is efficiency.
- -20.2% ROA vs ANTX's -47.3%, ROIC -23.2% vs -61.1%
Best for: efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ANTX | 189.3% revenue growth vs ENTA's -3.4% |
| Quality / Margins | ANTX | 4.7% margin vs ENTA's -89.6% |
| Stability / Safety | ANTX | Beta 0.42 vs ENTA's 1.27 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ANTX | +319.5% vs ENTA's +60.6% |
| Efficiency (ROA) |  ENTA | -20.2% ROA vs ANTX's -47.3%, ROIC -23.2% vs -61.1% |
ANTX vs ENTA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ANTX vs ENTA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLANTXLAGGINGENTA
ENTAEnanta Pharmaceutical…
2leads
ANTXAN2 Therapeutics, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs ENTAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ENTA1/1
Valuation MetricsMultiples, price ratios, and targets
ANTX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ENTA4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ANTX6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ENTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ENTA and ANTX operate at a comparable scale, with $69M and $0 in trailing revenue.
| Metric | ANTXAN2 Therapeutics,… | ENTAEnanta Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $69M |
| EBITDAEarnings before interest/tax | -$37M | -$55M |
| Net IncomeAfter-tax profit | -$35M | -$62M |
| Free Cash FlowCash after capex | -$31M | -$10M |
| Gross MarginGross profit ÷ Revenue | — | +98.3% |
| Operating MarginEBIT ÷ Revenue | — | -87.2% |
| Net MarginNet income ÷ Revenue | — | -89.6% |
| FCF MarginFCF ÷ Revenue | — | -13.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +15.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +17.1% | +57.5% |
ENTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ANTX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ANTXAN2 Therapeutics,… | ENTAEnanta Pharmaceut… |
|---|---|---|
| Market CapShares × price | $130M | $276M |
| Enterprise ValueMkt cap + debt − cash | $110M | $445M |
| Trailing P/EPrice ÷ TTM EPS | -4.09x | -3.10x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 4.23x |
| Price / BookPrice ÷ Book value/share | 2.70x | 3.92x |
| Price / FCFMarket cap ÷ FCF | — | — |
ANTX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ENTA leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
ANTX delivers a -52.3% return on equity — every $100 of shareholder capital generates $-52 in annual profit, vs $-64 for ENTA. On the Piotroski fundamental quality scale (0–9), ENTA scores 3/9 vs ANTX's 1/9, reflecting mixed financial health.
| Metric | ANTXAN2 Therapeutics,… | ENTAEnanta Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -52.3% | -64.0% |
| ROA (TTM)Return on assets | -47.3% | -20.2% |
| ROICReturn on invested capital | -61.1% | -23.2% |
| ROCEReturn on capital employed | -56.4% | -31.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | — | 3.11x |
| Net DebtTotal debt minus cash | -$20M | $169M |
| Cash & Equiv.Liquid assets | $20M | $32M |
| Total DebtShort + long-term debt | $0 | $201M |
| Interest CoverageEBIT ÷ Interest expense | — | -5.15x |
ENTA leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ANTX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANTX five years ago would be worth $3,078 today (with dividends reinvested), compared to $2,498 for ENTA. Over the past 12 months, ANTX leads with a +319.5% total return vs ENTA's +60.6%. The 3-year compound annual growth rate (CAGR) favors ANTX at -13.1% vs ENTA's -22.5% — a key indicator of consistent wealth creation.
| Metric | ANTXAN2 Therapeutics,… | ENTAEnanta Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +327.0% | -17.5% |
| 1-Year ReturnPast 12 months | +319.5% | +60.6% |
| 3-Year ReturnCumulative with dividends | -34.4% | -53.4% |
| 5-Year ReturnCumulative with dividends | -69.2% | -75.0% |
| 10-Year ReturnCumulative with dividends | -39.4% | -48.3% |
| CAGR (3Y)Annualised 3-year return | -13.1% | -22.5% |
ANTX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ANTX and ENTA each lead in 1 of 2 comparable metrics.
Risk & Volatility
ANTX is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than ENTA's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ANTXAN2 Therapeutics,… | ENTAEnanta Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.42x | 1.27x |
| 52-Week HighHighest price in past year | $6.91 | $17.15 |
| 52-Week LowLowest price in past year | $1.00 | $6.44 |
| % of 52W HighCurrent price vs 52-week peak | +68.6% | +69.4% |
| RSI (14)Momentum oscillator 0–100 | 54.5 | 35.9 |
| Avg Volume (50D)Average daily shares traded | 261K | 169K |
Evenly matched — ANTX and ENTA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ANTX as "Buy" and ENTA as "Buy". Consensus price targets imply 305.0% upside for ENTA (target: $48) vs 89.9% for ANTX (target: $9).
| Metric | ANTXAN2 Therapeutics,… | ENTAEnanta Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $48.20 |
| # AnalystsCovering analysts | 8 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ENTA leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ANTX leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallAN2 Therapeutics, Inc. (ANTX)Leads 2 of 6 categories
Loading custom metrics...
ANTX vs ENTA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ANTX or ENTA a better buy right now?
Analysts rate AN2 Therapeutics, Inc.
(ANTX) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ANTX or ENTA?
Over the past 5 years, AN2 Therapeutics, Inc.
(ANTX) delivered a total return of -69. 2%, compared to -75. 0% for Enanta Pharmaceuticals, Inc. (ENTA). Over 10 years, the gap is even starker: ANTX returned -39. 4% versus ENTA's -48. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ANTX or ENTA?
By beta (market sensitivity over 5 years), AN2 Therapeutics, Inc.
(ANTX) is the lower-risk stock at 0. 42β versus Enanta Pharmaceuticals, Inc. 's 1. 27β — meaning ENTA is approximately 200% more volatile than ANTX relative to the S&P 500.
04Which is growing faster — ANTX or ENTA?
On earnings-per-share growth, the picture is similar: AN2 Therapeutics, Inc.
grew EPS 32. 6% year-over-year, compared to 29. 9% for Enanta Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ANTX or ENTA?
AN2 Therapeutics, Inc.
(ANTX) is the more profitable company, earning 0. 0% net margin versus -125. 4% for Enanta Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANTX leads at 0. 0% versus -130. 7% for ENTA. At the gross margin level — before operating expenses — ENTA leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ANTX or ENTA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ANTX or ENTA better for a retirement portfolio?
For long-horizon retirement investors, AN2 Therapeutics, Inc.
(ANTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 42)). Both have compounded well over 10 years (ANTX: -39. 4%, ENTA: -48. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ANTX and ENTA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.